The authors sincerely regret to report two typographical errors in the published article. 1. In the “Introduction” section: The sentence: “Given the complementary mechanisms of PD-1 and CTLA-4 inhibition [8], and the clinical potential of combination therapy with improved tolerability, the fixed-dose combination of low-dose nurulimab and prolgolimab (3:1 ratio) was investigated in the phase II OBERTON trial (NCT05732805).” Should be corrected to: “Given the complementary mechanisms of PD-1 and CTLA-4 inhibition [8], and the clinical potential of combination therapy with improved tolerability, the fixed-dose combination of low-dose nurulimab and prolgolimab (1:3 ratio) was investigated in the phase II OBERTON trial (NCT05732805).” The ratio of low-dose nurulimab to prolgolimab was incorrectly stated as 3:1 and should be 1:3.2. Corresponding Author's Primary Affiliation in the corresponding author details: The primary affiliation for the corresponding author was incorrectly listed. The correct primary affiliation should be JSC BIOCAD, Russian Federation.The authors apologize for any inconvenience or confusion these errors may have caused. © 2025 Elsevier B.V., All rights reserved.